CClinicalTrials.gg
CompletedNCT07200388Updated May 12, 2026

How Emotional Granularity Helps Build Resilience in Young and Middle-Aged Colorectal Cancer Survivors

An observational study in Colorectal Cancer (CRC), sponsored by The Hong Kong Polytechnic University. Completed at 3 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by The Hong Kong Polytechnic University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
242
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study aims to understand how the ability to identify and describe specific emotions (called "emotional granularity") influences coping and adaptation ("resilience") in young and middle-aged colorectal cancer survivors.

The main questions to be answer are:

  1. How does emotional granularity help build resilience during cancer recovery?
  2. How does emotion regulation contribute to resilience building?
  3. What specific emotional needs and challenges do survivors experience?

This is an observational study where no experimental treatments are provided. Participants will complete an online questionnaire about background, emotions, ways of managing emotions, and ability to cope with stress. A subset of participants will then be invited to take part in a private, 30-60 minute interview to share personal experiences and feelings in more detail.

Read the detailed description

Colorectal cancer (CRC) survivors, particularly young and middle-aged adults, frequently experience substantial emotional and psychosocial challenges after treatment completion. Emotional distress, social role disruption, and difficulties in adapting to long-term survivorship may negatively affect resilience and quality of life. Emotional granularity, defined as the ability to identify and differentiate subtle emotional experiences, has been proposed as a potential mechanism that may enhance adaptive emotion regulation and psychological resilience.

This sequential mixed-methods study aims to investigate the relationship between emotional granularity, emotion regulation, and resilience among young and middle-aged CRC survivors, and to explore survivors' emotional experiences and psychosocial support needs to inform future intervention development.

The study consists of two phases. In the first phase, a cross-sectional survey will be conducted among young and middle-aged CRC survivors recruited from teaching hospitals affiliated with Soochow University and Jiangsu University in Suzhou, Jiangsu Province, China. Participants will complete validated Chinese-language questionnaires assessing emotional granularity, emotion regulation difficulties, and resilience. Mediation analysis will be performed to examine whether emotion regulation mediates the association between emotional granularity and resilience.

In the second phase, purposive sampling will be used to recruit participants with varying levels of emotional granularity scores from the quantitative phase. Semi-structured individual interviews will be conducted to explore participants' emotional experiences, coping strategies, emotional support needs, and perceptions regarding emotion-focused interventions. Qualitative findings will be integrated with quantitative results to provide evidence supporting the future development of emotional granularity-based psychosocial interventions for CRC survivors.

02

Conditions studied

  • Colorectal Cancer (CRC)

Keywords

  • Emotional Granularity
  • Psychological Resilience
  • Mixed Methods Research
  • Young and Middle-Aged Adults
  • Colorectal Neoplasms
  • Emotional Regulation
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,458 are open to participants now.

This study's enrollment of 242 is close to the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 659 studies on the registry; 250 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of samples and data obtained from three major regional tertiary hospitals in Suzhou, Jiangsu Province:

  1. The First Affiliated Hospital of Soochow University: A leading comprehensive tertiary Grade A hospital and a major clinical, teaching, and research center in the region.
  2. The Second Affiliated Hospital of Soochow University: Another key comprehensive tertiary Grade A hospital providing high-level medical services to the urban population.
  3. Kunshan First People's Hospital Affiliated to Jiangsu University: A premier tertiary Grade A hospital representing the high-quality healthcare infrastructure of county-level cities within the Suzhou administrative area.

This selection encompasses top-tier medical institutions from both the central urban district of Suzhou and a developed county-level city (Kunshan), ensuring a representative and diverse sample of the patient population and healthcare delivery within the Suzhou region.

Inclusion criteria

  • Young and middle-aged adult patients (age in the range of 18-60 years);
  • Patients diagnosed with CRC;
  • Patients have completed primary treatments (e.g., surgery, chemotherapy, and/or radiotherapy) without experiencing a recurrence of CRC;
  • Patients able to use a smartphone and agree to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who have not been informed of their cancer diagnosis due to family decision to withhold information;
  • Patients suffering from severe conditions that may affect participation or assessment, such as significant cognitive impairment, psychiatric disorders, or communication disorder.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
242 participants (actual)
Patient registry
No

Groups and cohorts

  • Young and Middle-Aged CRC Survivors

    This single cohort consists of young and middle-aged adult survivors of colorectal cancer. All participants will complete the quantitative survey phase. A subset of participants, purposively sampled based on their survey scores, will then be invited to participate in the qualitative interview phase. There is no intervention administered; this is an observational study examining the relationships between emotional granularity, emotion regulation, and resilience.

06

What researchers measure

Primary outcomes

  1. Level of Resilience

    Resilience will be measured by the total score on the Chinese version of the 10-item Connor-Davidson Resilience Scale (CD-RISC-10). Scores range from 0 to 40, with higher scores indicating higher levels of resilience.

    Time frame: Baseline (Day 1, at questionnaire completion for each participant)

Secondary outcomes

  1. Emotional Granularity Score

    Emotional granularity (the ability to differentiate emotional experiences) will be measured by the total score on the Chinese version of the Range and Differentiation of Emotional Experience Scale (RDEES). The scale contains 11 items, and higher scores indicate a greater ability to differentiate between subtle emotions.

    Time frame: Baseline (Day 1, at questionnaire completion for each participant)

  2. Emotion Regulation Difficulties Score

    Difficulties in emotion regulation will be measured by the total score on the Chinese version of the Difficulties in Emotion Regulation Scale (DERS). The scale contains 36 items, and higher scores indicate greater problems with emotion regulation.

    Time frame: Baseline (Day 1, at questionnaire completion for each participant)

Other outcomes

  1. Qualitative Themes on Emotional Needs

    Themes and patterns identified through thematic analysis of semi-structured interviews regarding survivors' emotional experiences, needs, and coping strategies.

    Time frame: Post-questionnaire phase (within approximately 2-6 weeks after baseline, depending on scheduling of interviews)

07

Study locations

3 sites
  • Kunshan First People's Hospital Affiliated to Jiangsu University
    Suzhou, Jiangsu 215000, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
  • The First Affiliated Hospital of Soochow University
    Suzhu, Jiangsu 215000, China
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Sep 5, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — A final decision regarding sharing individual participant data (IPD) has not yet been finalized. This is due to the need for further internal discussions and consultations with all collaborating institutions, particularly regarding compliance with cross-border data transfer regulations under China's Personal Information Protection Law (PIPL) and ethical guidelines governing participant privacy. Additionally, the feasibility of robust de-identification processes and secure data-sharing mechanisms is being evaluated to ensure participant confidentiality. The final decision will be determined before study completion and will align with journal requirements, participant consent agreements, and institutional policies.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07200388
Lead sponsor
The Hong Kong Polytechnic University
Collaborators
The First Affiliated Hospital of Soochow University, Second Affiliated Hospital of Soochow University, Kunshan First People's Hospital Affiliated to Jiangsu University
Responsible party
Dr Joyce Chung (Associate Professor, The Hong Kong Polytechnic University) — Principal investigator
First posted
Oct 1, 2025
Start date
Sep 30, 2025
Primary completion
May 6, 2026
Completion
May 6, 2026
Last update
May 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion